Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

BACKGROUND: Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly sought. METHODS: Medical records of 100 patients with CML who were in MR(4.5) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamoun, Kamal, Kantarjian, Hagop, Atallah, Rami, Gonzalez, Graciela Nogueras, Issa, Ghayas C., Rios, Mary Beth, Garcia-Manero, Guillermo, Borthakur, Gautam, Ravandi, Farhad, Jain, Nitin, Daver, Naval, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan, Pemmaraju, Naveen, Jabbour, Elias, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318861/
https://www.ncbi.nlm.nih.gov/pubmed/30606227
http://dx.doi.org/10.1186/s13045-018-0686-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318861/
https://www.ncbi.nlm.nih.gov/pubmed/30606227
http://dx.doi.org/10.1186/s13045-018-0686-1

Ejemplares similares